Table 1. Demographics of donors and recipients and graft survival with anti-CD40 Ab-primates.
Demographics of anti-CD40 Ab-primates are presented. Rejected controls given topical and systemic steroid or steroid with tacrolimus, are included as a reference for use in comparison of memory T cell, antibody or complement responses.
| Recipients | Donors | Immuno-suppressive Regimen | Graft Survival (days) | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Age (months) | Body Weight (kg) | ABO type | Age (months) | ABO type | |||
| Anti-CD40 1 | 140 | 6.32 | B | 28 | A | Topical prednisolone+ Subconjunctival Dexamethasone+ Intramuscular Methylprednisolone+ IVIG+ Intravenous anti-CD40 Ab | >389 |
| Anti-CD40 2 | 74 | 7.12 | A | 28 | A | >382 | |
| Anti-CD40 3 | 56 | 5.02 | AB | 30 | A | >236 | |
| Anti-CD40 4 | 57 | 5.60 | B | 28 | A | >201 | |
| Anti-CD40 5 | 57 | 4.80 | B | 28 | A | >61 | |
| Mean ± SD | 56.7±0.58 | 5.78±0.96 | 28.40±0.89 | MST: Undefined | |||
|
| |||||||
| Control 1* | 48 | 5.48 | A | 37 | A | Topical prednisolone+ Subconjunctival Dexamethasone+ Intramuscular Methylprednisolone | 28 |
| Control 2* | 54 | 4.90 | AB | 35 | A | 29 | |
| Control 3* | 137 | 4.94 | B | 31 | A | 21 | |
|
| |||||||
| Control 4 | 57 | 4.2 | AB | 42 | A | Topical prednisolone+ Subconjunctival Dexamethasone+ Intramuscular Methylprednisolone+ IVIG+Tacrolimus Intramuscular Tacrolimus | 32 |
|
| |||||||
| Mean ± SD | 74.0±42.2 | 4.88±0.45 | 36.25±3.96 | MST : 28.5 | |||
SD: standard deviation, MST: mean survival time
*
were adopted from previous study[19].